Cytokinetics clinical trial
WebMay 5, 2024 · We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, HCM and SMA. Company Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Our Vision Leadership … WebMay 6, 2024 · Cytokinetics is preparing for regulatory interactions for omecamtiv mecarbil, its novel cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil.
Cytokinetics clinical trial
Did you know?
WebClinical Trial Assistant, Cytokinetics San Francisco, California, United States. 88 followers 88 connections. Join to view profile Cytokinetics. San Francisco State University. Report this profile ... WebMay 19, 2024 · Known to have received CK-2127107 or tirasemtiv in any previous clinical trial; ... Cytokinetics: ClinicalTrials.gov Identifier: NCT03160898 Other Study ID Numbers: CY 5022 : First Posted: May 19, 2024 Key Record Dates: Results First Posted: September 11, 2024: Last Update Posted: ...
WebThis Amendment No. 6 to the Agreement (this “Amendment No. 6”) is entered into as of June 11, 2013 (the “Amendment Effective Date”) by and between Cytokinetics, Incorporated (“Cytokinetics”), a Delaware corporation, having its principal place of business at 280 East Grand Ave., South San Francisco, California 94080 and Amgen Inc., a ... WebCytokinetics is developing omecamtiv mecarbil, a novel, selective cardiac myosin activator for the potential treatment for heart failure with reduced ejection fraction (HFrEF). Omecamtiv mecarbil stimulates cardiac …
WebJun 24, 2024 · SOUTH SAN FRANCISCO, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has informed the company... WebFeb 23, 2024 · Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy. …
WebAug 11, 2024 · Following promising results from a phase 2 clinical trial, Cytokinetics announced open enrollment for a new phase 3 trial dubbed COURAGE-ALS (NCT04944784), which will evaluate the efficacy and safety of its investigational agent reldesemtiv in patients with amyotrophic lateral sclerosis (ALS).
WebAficamten (formerly CK-3773274, or CK-274) is an investigational, novel, oral, small molecule cardiac myosin inhibitor discovered by company scientists independent of its collaborations, for the potential treatment of hypertrophic cardiomyopathies (HCM). flintstone push up popsWebJan 7, 2024 · Cytokinetics Investigators More Information Go to Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Zampieri M, Argiro A, Marchi A, Berteotti M, Targetti M, Fornaro A, Tomberli A, Stefano P, Marchionni N, Olivotto I. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. flintstone ready clinicWebAug 2, 2024 · Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical trial of omecamtiv mecarbil. Cytokinetics is also developing CK-274, a next-generation … greater sheepshead bay development corpWebApr 10, 2024 · It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated CYTK. Shares of the company have moved down 20.5% compared with the industry’s decline of 4.7%. flintstone real estate addis ababaWebMar 31, 2024 · Cytokinetics intends to notify all regulatory agencies and clinical trial investigators involved in COURAGE-ALS of these interim findings. The full data set from this trial is being analyzed and more details will be presented at an upcoming medical meeting. Conference Call and Webcast greater shankill partnership boardWebApr 10, 2024 · Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates, including the potential commencement of a Phase 3 clinical trial of aficamten in patients with nonobstructive hypertrophic cardiomyopathy in … greater shekinah glory church hickory ncWebFeb 28, 2024 · Cytokinetics is developing omecamtiv mecarbil, a cardiac muscle activator in patients with heart failure. Cytokinetics is also developing aficamten, a next-in-class … flintstone push-up pops